{"page_content": "Notes\nNote 23 \u2013 Change in working capital\nDKK thousand     2021  2020\nIncrease/decrease in receivables\n    -184\n,413\n -9\n,666\nIncrease/decrease in inventory\n    -33\n,067\n -45\n,700\nIncrease/decrease in payables\n    -10\n,876\n 39\n,720\nIncrease/decrease in other liabilities\n    -28\n,701\n 46\n,328\nChange in working capital\n    -257\n,057\n 30\n,682\nNote 24 \u2013 Allocation of result\nThe Board of Directors proposes that the parent company\u2019s 2021 net result of DKK -1,004.6 million (2020: \nDKK -826.8 million) be carried forward to next year by transfer to retained loss.\nNote 25 \u2013 Significant events after the balance sheet date\nPlease refer to note 36 in the consolidated financial statements.\nNote 26 \u2013 Approval of the annual report\nPlease refer to note 37 in the consolidated financial statements.Note 21 \u2013 Transactions with related parties\n\u2018Zealand Pharma A/S' related parties are the board of directors, executive management, and close mem-bers of the family of these persons. Refer to note 7 in the consolidated financial statements for remunera-tion of Board of Directors. Refer to note 3 in these parent company financial statements for remuneration of the executive management team.\nThe parent company had the following transactions with subsidiaries:\nDKK thousands\n    2021\n \n2020\nRevenue\n    168\n,713\n 138\n,396\nOther income\n    9\n,186\n 35\n,500\nResearch and development expenses\n    54\n,055\n 0\nSale and mark\neting expenses\n    365\n,851\n 327\n,829\nAdmin Expenses\n    92,1\n49\n 0\nReceivables\n    1\n44,904\n 325\n,645\nPayables\n    59\n,078\n 359\n,869\nNote 22 \u2013 Adjustments for non-cash items\nDKK thousand     2021  2020\nDepreciation\n    28\n,678\n 26\n,293\nWarrant compensation expenses\n    68\n,577\n 16\n,273\nIncome tax receipt\n    1,\n426\n 0\nFinancial income\n    -8\n,596\n 0\nFinancial expenses\n    17\n,436\n 5\n,327\nNet loss on sale of fixed assets\n    2,258\n 0\nF\nair value adjustments\n    -2,\n007\n 0\nEx\nchange rate adjustments\n    19\n,451\n 9\n,623\nTotal adjustments\n    127\n,223\n 57\n,516112\nZealand Pharma  \u221e  Annual Report 2021Par Fin \u2013 Note 22-27", "metadata": {"source": "NASDAQ_ZEAL_2021.pdf", "page": 111, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}